While previous studies had shown that FGF23 is independently associated with cardiovascular mortality and with the composite endpoint of death or heart transplantation in patients with systolic HF [9, 11], a recent post-hoc analysis of the Trial of Intensified vs. Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) has questioned the predictive power of FGF23 [12]. The gene discussed is FGF23; the disease is congestive heart failure.